rb's naltrexone patent

My previous research has repeatedly led me to Reckitt Benckiser for being a candidate for using our transdermal technology to enhance Buprenorphine delivery and minimize the potential abuse of the drug in oral form.

A patent lodged by Reckitt Benckiser in May 2010 combines Buprenorphine with Naltrexone which provides the link to OBJ in ways of compound as well as in a timely manner as shown below:

Abstract:
An analgesic composition, in parenteral unit dosage form or in a unit dosage form suitable for delivery via the dermis or mucosa, comprises buprenorphine and an amount of naltrexone such that the ratio by weight of buprenorphine to naltrexone delivered to or reaching the plasma of a patient is in the range 100:1 to 5000:1. The analgesic action of the buprenorphine is potentiated by the low dose of naltrexone. Also provided are a method of treatment of pain and the use of buprenorphine and naltrexone for the manufacture of a medicament.

We clearly talk about a transdermal patch here.

Buprenorphine and Naltrexone patch patent



A year earlier OBJ had tested Naltrexone delivery enhanced by OBJ's dermaportation technology and published its results, amongst the leading scientists were Jeff and Heather.

The cumulative amount of Naltrexone permeated
through silicone membrane to the receptor compartment
by Dermaportation was impressive.

Enhanced Skin Permeation of Naltraxone



OBJ had tested Naltrexone on human epidermis ex-vivo with the following result:


Dermaportation was successful at delivering
naltrexone through excised human epidermis, with a
flux rate in the first 2 hours of 95 times that of passive
diffusion. Dermaportation has the potential to provide
a more effective and convenient delivery system for
naltrexone, than the current oral delivery method.

Dermaportation increases Naltraxone penetration


The timing here is interesting as the Naltrexone thread of news dries up after the Edwards/ Benson paper and allows RB to test further internaly for another year before committing the patent in 2010.

Now in 2011, we do receive allowance for our dermaportation technology in the US where RB dedicates research against opioid abuse to offset the effects of revenue losses of their expired patent protection for the Buprenorphine products Subutex and Suboxone.